Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation

Clinical Transplantation

Volumn 15, Issue SUPPL. 6, 2001, Pages 51-54

  Browne, Barry J ^a   Holt, Cynthia OP'T ^a   Emovon, Osemwegie E ^b  

^a Department of Surgery ^*  (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute rejection; Cyclosporine; Pharmacokinetics

Indexed keywords

COTRIMOXAZOLE; CREATININE; CYCLOSPORIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RANITIDINE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ADVERSE DRUG REACTION; AGED; ALLOGRAFT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOXICITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER METABOLISM; MAINTENANCE THERAPY; MALE; MICROEMULSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; STEROID THERAPY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 0035169309     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2001.0150s5051.x     Document Type: Article

References (18)

1. Cyclosporine
2. The pharmamacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients
3. Libetti. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion
4. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period
5. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
6. Effect of race on renal transplant outcome
7. Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection
8. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation
9. Biological effects of cyclosporin A: A new antilymphocytic agent
10. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
11. Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring
12. Absorption profiling. A novel method for monitoring neoral in kidney transplantation that reduces rejection and nephrotoxicity
13. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors
14. Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection
15. A comparison of kidney transplant survival in white and black recipients
16. Renal transplantation and the American black
17. The impact of acute rejection on long-term graft survival and outcome in 1347 primary renal transplants treated by three cyclosporin regimens
18. Predictors of long-term primary cadaveric renal transplant survival